首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Permeation enhancer dodecyl 6-(dimethylamino)hexanoate increases transdermal and topical delivery of adefovir: influence of pH, ion-pairing and skin species.
【24h】

Permeation enhancer dodecyl 6-(dimethylamino)hexanoate increases transdermal and topical delivery of adefovir: influence of pH, ion-pairing and skin species.

机译:渗透促进剂6-(二甲氨基)己酸十二烷基酯增加阿德福韦的透皮和局部递送:pH,离子对和皮肤种类的影响。

获取原文
获取原文并翻译 | 示例

摘要

Adefovir (9-(2-phosphonomethoxyethyl)adenine) is an acyclic nucleoside phosphonate currently used for the treatment of hepatitis B. The aim of this study was to evaluate the effect of permeation enhancer DDAK (6-dimethylaminohexanoic acid dodecyl ester) on the transdermal and topical delivery of adefovir. In porcine skin, DDAK enhanced adefovir flux 42 times with maximum at pH 5.8 suggesting ion pair formation. DDAK increased thermodynamic activity and stratum corneum/vehicle distribution coefficient of adefovir, as well as it directly decreased the skin barrier resistance. Maximal flux was observed already at 2% adefovir+1% DDAK. The results were confirmed in freshly excised human skin where DDAK enhanced adefovir flux 179 times to 8.9 microg/cm(2)/h. This rate of percutaneous absorption would allow for reaching effective plasma concentrations. After the topical application, adefovir concentrated in the stratum corneum with low penetration into the deeper skin layers from either aqueous or isopropyl myristate vehicle without the enhancer. With 1% DDAK, adefovir concentrations in the viable epidermis and dermis were 33-61 times higher. These results offer an attractive alternative to established routes of administration of adefovir and other acyclic nucleoside phosphonates.
机译:阿德福韦(9-(2-膦酰基甲氧基乙基)腺嘌呤)是一种无环核苷膦酸酯,目前用于治疗乙型肝炎。本研究的目的是评估渗透促进剂DDAK(6-二甲基氨基己酸十二烷基酯)对透皮的影响。和局部递送阿德福韦。在猪皮肤中,DDAK使阿德福韦的通量增加42倍,在pH 5.8时达到最大值,表明形成了离子对。 DDAK增加了阿德福韦的热力学活性和角质层/载体分布系数,并且直接降低了皮肤屏障抵抗力。在2%阿德福韦+ 1%DDAK处已经观察到最大通量。结果在刚切除的人皮肤中得到证实,其中DDAK将阿德福韦的通量提高了179倍,达到8.9 microg / cm(2)/ h。该经皮吸收速率将允许达到有效血浆浓度。局部应用后,阿德福韦在没有增强剂的情况下从肉豆蔻酸水溶液或肉豆蔻酸异丙酯中以较低的渗透率浓缩到角质层中,并渗入较深的皮肤层。 DDAK为1%时,阿德福韦在活表皮和真皮中的浓度高33-61倍。这些结果为阿德福韦和其他无环核苷膦酸酯的既定给药途径提供了有吸引力的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号